Table of Contents

BioDextris

COVID-19

BioDextris is developing an intranasal COVID-19 vaccine product with Oragenics.1)

1)
Sullivan, M., & Golodetz, K. (2021, March 9). Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine. Business Wire; Berkshire Hathaway. https://archive.ph/QrWCj